JMP Securities Reaffirms Market Outperform Rating for Lantheus (NASDAQ:LNTH)

Lantheus (NASDAQ:LNTH)‘s stock had its “market outperform” rating restated by equities research analysts at JMP Securities in a report released on Tuesday,Benzinga reports. They presently have a $112.00 target price on the medical equipment provider’s stock. JMP Securities’ price target points to a potential upside of 19.88% from the company’s previous close.

A number of other brokerages also recently issued reports on LNTH. Truist Financial reaffirmed a “buy” rating and set a $120.00 price target (down from $135.00) on shares of Lantheus in a report on Friday, November 8th. StockNews.com cut shares of Lantheus from a “buy” rating to a “hold” rating in a research note on Thursday, November 21st. Finally, The Goldman Sachs Group assumed coverage on shares of Lantheus in a report on Wednesday, December 18th. They set a “buy” rating and a $143.00 price target on the stock. One investment analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $131.86.

Lantheus Stock Up 0.9 %

Shares of NASDAQ LNTH opened at $93.43 on Tuesday. The company has a 50 day moving average of $89.57 and a 200 day moving average of $99.82. Lantheus has a twelve month low of $50.20 and a twelve month high of $126.89. The firm has a market cap of $6.50 billion, a P/E ratio of 15.55 and a beta of 0.46.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of LNTH. Wilmington Savings Fund Society FSB purchased a new stake in shares of Lantheus in the 3rd quarter worth $25,000. Signaturefd LLC grew its holdings in Lantheus by 40.5% during the third quarter. Signaturefd LLC now owns 319 shares of the medical equipment provider’s stock valued at $35,000 after purchasing an additional 92 shares during the period. Nkcfo LLC purchased a new stake in Lantheus in the second quarter worth about $47,000. UMB Bank n.a. increased its position in Lantheus by 42.1% in the third quarter. UMB Bank n.a. now owns 425 shares of the medical equipment provider’s stock worth $47,000 after buying an additional 126 shares in the last quarter. Finally, Kathleen S. Wright Associates Inc. bought a new position in shares of Lantheus in the third quarter worth about $51,000. Hedge funds and other institutional investors own 99.06% of the company’s stock.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.